DIABETOLOGIA：前列腺素E2/EP2受体信号通路在糖尿病大鼠模型中促进糖尿病视网膜病变-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2021-07-16 星晓

新机制和方向

0 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-12-07 ms9608593228839890

#DIA#

82 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-11-30 ms5439512287675881

#BET#

90 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-06-03 makuansheng

#前列腺素#

97 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-08 zutt

#视网膜#

68 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-08 zhanfl

#视网膜病变#

79 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-08 wgx310

#信号通路#

96 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-08 budeshao

#前列腺素E2#

132 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-07 misszhang

谢谢MedSci提供最新的资讯

141 0

[GetPortalCommentsPageByObjectIdResponse(id=1000159, encodeId=5543100015950, content=新机制和方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f42486110, createdName=星晓, createdTime=Fri Jul 16 20:50:10 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639098, encodeId=c24b1639098ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Dec 07 23:53:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761106, encodeId=472a1e611069d, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Nov 30 19:53:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744858, encodeId=b9a31e448589d, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Mon Jun 03 20:53:00 CST 2019, time=2019-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270190, encodeId=183a12e019000, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413983, encodeId=bb2e141398301, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539743, encodeId=7e6d1539e43e3, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569533, encodeId=61ee1569533ef, content=<a href='/topic/show?id=62ff32560b5' target=_blank style='color:#2F92EE;'>#前列腺素E2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32560, encryptionId=62ff32560b5, topicName=前列腺素E2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d4015518959, createdName=budeshao, createdTime=Wed May 08 13:53:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042420, encodeId=a61d104242099, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047705, encodeId=cf6d104e7051c, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue May 07 01:53:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

2019-05-07 CHANGE

梅斯里提供了很多疾病的模型计算公式，赞一个！

105 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

DIABETOLOGIA：前列腺素E2/EP2受体信号通路在糖尿病大鼠模型中促进糖尿病视网膜病变

相关资讯

科室

工具

服务